


Technology Advisory Committee C Interests Register Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia [ID3860]

Publication Date: 31/05/2023

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
Professor Matthew Stevenson	Committee member	Direct financial	Professor Stevenson has undertaken work for AstraZeneca Rare Diseases in an unrelated disease area, Myasthenia Gravis.	20/02/2023	N/A	It was agreed that his declarations would not prevent Professor Stevenson from participating in discussions on this appraisal.
Dr Richard Nicholas	Committee member	Direct financial	Dr Nicholas has attended paid advisory boards with Roche in an unrelated area (MS).	21/02/2023	N/A	It was agreed that his declarations would not prevent Dr Nicholas from participating in discussions on this appraisal.
Michael Chambers	Committee member	Direct financial	Mr Chambers has co- ordinated a training programme for Roche in Real World Evidence, which did not consider any Roche products, participated in an advisory panel for Pfizer in an unrelated disease area	23/02/2023	N/A	It was agreed that his declarations would not prevent Mr Chambers from participating in discussions on this appraisal.



Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
			(prostate cancer) and provided advice to Sanofi in an unrelated disease area (COPD).			
Dr Steven Lloyd	Committee member	Direct financial	Dr Lloyd has provided educational advice on respiratory pathways and vaccinations for Pfizer, Roche and Viatris and was paid for items of education.	14/03/2023	N/A	It was agreed that his declarations would not prevent Dr Lloyd from participating in discussions on this appraisal.
Dr Nicolas Martinez-Calle	Clinical expert	Direct financial	 Pr Martinez-Calle has: received travel support from Takeda, Abbvie and AstraZeneca. received speaker bureau honoraria from AbbVie, Janssen, AstraZeneca and Roche. taken part in advisory boards for Takeda, Abbvie and Beigene. 	24/04/2022 14/03/2023	N/A	It was agreed that her declarations would not prevent Dr Martinez-Calle from providing expert advice to the committee.



Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
			received a research grant from Celgene in 2015.			
Professor Nagesh Kalakonda	Clinical expert	Direct financial	Professor Kalakonda has received speaker fees from Janssen for participation in an educational event focused on ibrutinib and CLL.	04/05/2022	N/A	It was agreed that her declarations would not prevent Professor Kalakonda from providing expert advice to the committee.
Nick York	Patient expert	Indirect financial	Mr York's employer Leukaemia Care has received funding and honorarium from Janssen and AbbVie, honorarium from AstraZeneca UK, emergency funding from Gilead Sciences and funding from Pfizer for support services.	03/11/2022	N/A	It was agreed that her declarations would not prevent Mr York from providing expert advice to the committee.
Steve Abrahams	Patient expert	Non-financial professional and personal	Mr Abrahams is a trustee of CLL Support.	14/03/2023	N/A	It was agreed that her declarations would not prevent Mr Abrahams from providing expert advice to the committee.